VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
FactSet Research Systems Inc. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
FactSet Research Systems Inc.
FDS · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into FactSet Research Systems Inc.'s moat claims, evidence, and risks.
View FDS analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: FactSet Research Systems Inc. leads (85 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: FactSet Research Systems Inc. has 2 segments; Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: FactSet Research Systems Inc. has 6 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
FactSet Research Systems Inc.
Hosted Platform (Workstations & Analytics)
Financial data and analytics platforms for investment professionals
Global
Institutional investors and financial institutions
Software and data platform vendor
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
FactSet Research Systems Inc. strengths
Gilead Sciences, Inc. strengths
Segment mix
FactSet Research Systems Inc. segments
Full profile >Hosted Platform (Workstations & Analytics)
Oligopoly
Identifier Platform (CUSIP Global Services)
Quasi-Monopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.